Literature DB >> 16841087

Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells.

C Simone, A Giordano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16841087     DOI： 10.1038/sj.cdd.4402008

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  9 in total

1.  Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

Authors:  Caroline M Robb; Jacob I Contreras; Smit Kour; Margaret A Taylor; Mohammad Abid; Yogesh A Sonawane; Muhammad Zahid; Daryl J Murry; Amarnath Natarajan; Sandeep Rana
Journal:  Chem Commun (Camb)       Date:  2017-07-04       Impact factor: 6.222

2.  Selective degradation of CDK6 by a palbociclib based PROTAC.

Authors:  Sandeep Rana; Mourad Bendjennat; Smit Kour; Hannah M King; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

Review 3.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

4.  Cyclin T1 overexpression induces malignant transformation and tumor growth.

Authors:  Cristian Moiola; Paola De Luca; Kevin Gardner; Elba Vazquez; Adriana De Siervi
Journal:  Cell Cycle       Date:  2010-08-01       Impact factor: 4.534

Review 5.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

Review 6.  The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma.

Authors:  Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

7.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

8.  Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.

Authors:  Yeming Han; Shanshan Zhao; Yaoqin Gong; Guihua Hou; Xi Li; Li Li
Journal:  Oncotarget       Date:  2016-01-12

Review 9.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.